FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187984100> ?p ?o ?g. }

• W2187984100 abstract "Purpose: Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan. Patients and Methods: Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5.0 mg/m 2 by intravenous (IV) infusion over 30 minutes on days 1 to 5 with ara-C 1.0 mg/m 2 /d IV over 2 hours on days 1 to 5, idarubicin 12 mg/m 2 by 5 minute IV infusion on days 1 to 3, or topotecan 1.0 mg/m 2 as an continuous IV infusion on days 1 to 5. Doses were then adjusted to define DLT for each combination. Results: Eighty-seven patients (68 AML, eight MDS, 11 CML-BP) were treated. DLTs were hepatic transaminitis, hyperbilirubinemia, and hand foot syndrome (HFS) on the troxacitabine plus ara-C combination. The recommended phase II doses were 6 mg/m 2 once a day for 5 days and 1.0g/m 2 once a day for 5 days, respectively. DLTs were diarrhea, rash, and mucositis on the troxacitabine plus topotecan combination. The recommended phase II doses were 4 mg/m 2 once a day for 5 days and 0.75 mg/m 2 once a day for 5 days, respectively. DLTs were HFS, rash, and mucositis on the troxacitabine plus idarubicin combination. The recommended phase II doses were 4 mg/m 2 once a day for 5 days and 9 mg/m 2 once a day for 3 days, respectively. Among 74 evaluable patients with AML or MDS, 10 (13%) achieved complete remission and four (5%) had hematologic improvement. Two of 11 (18%) evaluable patients with CML-BP returned to chronic phase. Conclusion: Troxacitabine-based combinations had significant antileukemic activity. J Clin Oncol 21:1050-1056. © 2003 by American Society of Clinical Oncology." @default.
• W2187984100 created "2016-06-24" @default.
• W2187984100 creator A5005358222 @default.
• W2187984100 creator A5015101485 @default.
• W2187984100 creator A5021277289 @default.
• W2187984100 creator A5028026524 @default.
• W2187984100 creator A5038307470 @default.
• W2187984100 creator A5040095008 @default.
• W2187984100 creator A5046097970 @default.
• W2187984100 creator A5057920623 @default.
• W2187984100 creator A5061026876 @default.
• W2187984100 creator A5061285204 @default.
• W2187984100 creator A5090435894 @default.
• W2187984100 date "2003-01-01" @default.
• W2187984100 modified "2023-10-15" @default.
• W2187984100 title "Randomized P hase I /II S tudy o f T roxacitabine C ombined W ith Cytarabine, I darubicin, o r T opotecan i n P atients W ith Refractory M yeloid L eukemias" @default.
• W2187984100 cites W1501742295 @default.
• W2187984100 cites W1518100747 @default.
• W2187984100 cites W1558518646 @default.
• W2187984100 cites W1562405218 @default.
• W2187984100 cites W1571638899 @default.
• W2187984100 cites W1596537940 @default.
• W2187984100 cites W1814791463 @default.
• W2187984100 cites W1919288105 @default.
• W2187984100 cites W1936026926 @default.
• W2187984100 cites W1939358691 @default.
• W2187984100 cites W1971677598 @default.
• W2187984100 cites W1985052461 @default.
• W2187984100 cites W1995900951 @default.
• W2187984100 cites W1996376265 @default.
• W2187984100 cites W2001967406 @default.
• W2187984100 cites W2024382021 @default.
• W2187984100 cites W2030873172 @default.
• W2187984100 cites W2032707644 @default.
• W2187984100 cites W2040650458 @default.
• W2187984100 cites W2048265963 @default.
• W2187984100 cites W2067336955 @default.
• W2187984100 cites W2073746430 @default.
• W2187984100 cites W2085758836 @default.
• W2187984100 cites W2097111310 @default.
• W2187984100 cites W2138468010 @default.
• W2187984100 cites W2139407325 @default.
• W2187984100 cites W2142408819 @default.
• W2187984100 cites W2160752946 @default.
• W2187984100 cites W2169452890 @default.
• W2187984100 cites W2169884507 @default.
• W2187984100 cites W2299562055 @default.
• W2187984100 cites W2333633096 @default.
• W2187984100 cites W2412174789 @default.
• W2187984100 cites W2466569700 @default.
• W2187984100 cites W75397567 @default.
• W2187984100 cites W151010937 @default.
• W2187984100 cites W2464115036 @default.
• W2187984100 hasPublicationYear "2003" @default.
• W2187984100 type Work @default.
• W2187984100 sameAs 2187984100 @default.
• W2187984100 citedByCount "0" @default.
• W2187984100 crossrefType "journal-article" @default.
• W2187984100 hasAuthorship W2187984100A5005358222 @default.
• W2187984100 hasAuthorship W2187984100A5015101485 @default.
• W2187984100 hasAuthorship W2187984100A5021277289 @default.
• W2187984100 hasAuthorship W2187984100A5028026524 @default.
• W2187984100 hasAuthorship W2187984100A5038307470 @default.
• W2187984100 hasAuthorship W2187984100A5040095008 @default.
• W2187984100 hasAuthorship W2187984100A5046097970 @default.
• W2187984100 hasAuthorship W2187984100A5057920623 @default.
• W2187984100 hasAuthorship W2187984100A5061026876 @default.
• W2187984100 hasAuthorship W2187984100A5061285204 @default.
• W2187984100 hasAuthorship W2187984100A5090435894 @default.
• W2187984100 hasConcept C121332964 @default.
• W2187984100 hasConcept C126322002 @default.
• W2187984100 hasConcept C142424586 @default.
• W2187984100 hasConcept C2776694085 @default.
• W2187984100 hasConcept C2778041864 @default.
• W2187984100 hasConcept C2778496288 @default.
• W2187984100 hasConcept C2778570526 @default.
• W2187984100 hasConcept C2778729363 @default.
• W2187984100 hasConcept C2779117419 @default.
• W2187984100 hasConcept C71924100 @default.
• W2187984100 hasConcept C87355193 @default.
• W2187984100 hasConcept C90924648 @default.
• W2187984100 hasConceptScore W2187984100C121332964 @default.
• W2187984100 hasConceptScore W2187984100C126322002 @default.
• W2187984100 hasConceptScore W2187984100C142424586 @default.
• W2187984100 hasConceptScore W2187984100C2776694085 @default.
• W2187984100 hasConceptScore W2187984100C2778041864 @default.
• W2187984100 hasConceptScore W2187984100C2778496288 @default.
• W2187984100 hasConceptScore W2187984100C2778570526 @default.
• W2187984100 hasConceptScore W2187984100C2778729363 @default.
• W2187984100 hasConceptScore W2187984100C2779117419 @default.
• W2187984100 hasConceptScore W2187984100C71924100 @default.
• W2187984100 hasConceptScore W2187984100C87355193 @default.
• W2187984100 hasConceptScore W2187984100C90924648 @default.
• W2187984100 hasLocation W21879841001 @default.
• W2187984100 hasOpenAccess W2187984100 @default.
• W2187984100 hasPrimaryLocation W21879841001 @default.
• W2187984100 hasRelatedWork W1752976675 @default.
• W2187984100 hasRelatedWork W2008439214 @default.
• W2187984100 hasRelatedWork W2091932491 @default.
• W2187984100 hasRelatedWork W2223840000 @default.

• next